TRANSFORM-1: This phase III trial is testing the combination of two targeted cancer drugs (Ruxolitinib and Navitoclax) to see if it is better than using one targeted cancer drug (Ruxolitinib) to treat people with myelofibrosisA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)

Summary

Navitoclax is an investigational drug for the treatment of myelofibrosis. Participants in this study are divided into two groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of myelofibrosis will be enrolled. Eligible participants will receive an oral navitoclax tablet with an oral ruxolitinib tablet or oral ruxolitinib tablet with an oral placebo (no active drug) tablet and treatment may continue till the participant cannot tolerate the study drug, or benefit is not achieved, or other reasons which qualify for discontinuation of the study drug.